On February 27, 2025 RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, reported the presentation of a business update by Guy Goldberg, RedHill’s Chief Business Officer, highlighting recent significant corporate activity, R&D advances and commercial progress with Talicia, at the Sachs Associates’ 18th Annual European Life Sciences CEO Forum in Zurich (Press release, RedHill Biopharma, FEB 27, 2025, View Source [SID1234650728]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We have had a very positive start to 2025, making significant progress on multiple fronts. We have just announced the out-licensing of RHB-102 to Hyloris, in a deal worth up to $60 million in potential milestone payments plus additional royalties on revenues. We also recently announced the initiation of a Bayer-funded Phase 2 clinical study of opaganib in combination with Bayer’s darolutamide for advanced prostate cancer, for which there are very limited options. This is in addition to the multiple U.S. government- and academia-supported R&D programs with key 2025 potential catalysts, including for radiation injury protection, oncology, and various pandemic preparedness indications," said Guy Goldberg, RedHill’s Chief Business Officer. "The commercial team are working equally hard on cementing, and building on, Talicia’s position as the number one branded H. pylori therapy. Subject to the successful completion of our ongoing discussions, we expect to substantially reduce Talicia’s COGS, directly boosting the bottom line. Other recent achievements include the Humana Part D win, adding another eight million Medicare lives; inclusion as first line option in the new ACG guideline; and the FDA sNDA approval to switch to a more convenient TID dosing. There are also opportunities for Talicia opening up in new markets outside of the U.S. and the recent commercial launch in the UAE, and we are evaluating additional marketing authorization applications in other countries. Talicia has now surpassed the 100,000 prescriptions milestone, our ground-breaking warranty program, with minimal claimed refunds, reflects a positive experience, and now, with new potential markets on the horizon, we are optimistic about the future for Talicia and the value it can deliver."
The presentation was available for registered attendees only.